Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients

Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients.

The purpose of this study is to investigate the intra-saliva penetration of voriconazole in different subpopulations. The goal is to develop, optimize and validate an easy, non-invasive and painless procedure for Therapeutic Drud Monitoring of voriconazole that can be used in children, ambulatory patients and in patients in whom blood drawing is difficult.

Inclusion Criteria:

• patients from the adult hematology ward treated with voriconazole
• pediatric patients treated with voriconazole, age 5-18 years
• patients from the pneumology ward treated with voriconazole

Exclusion Criteria:

• Age under 5 years
• Women who are pregnant or lactating
• Mucositis stage 3 or 4 (WHO)
• Patients which received the following drugs within 14 days before study entry: rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz and barbiturates.
• Patients which received the following drugs within 24hours before study entry: quinidine, ergotamine, sirolimus, saquinavir, amprenavir, nelfinavir, ritonavir and sulphonylureas.